ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Session » Osteoporosis and Metabolic Bone Disease

Meeting: 2012 ACR/ARHP Annual Meeting

Abstract Number: 819
Trajectories of Change in Physical Function: Effects On Fractures and Mortality
Abstract Number: 820
In Rheumatoid Arthritis Incident Fractures Are Associated with an Increased Risk of Cardiovascular Events
Abstract Number: 821
Association of Serum Uric Acid and Incident Fractures in Elderly Men
Abstract Number: 822
Greater Than Expected Increased Mortality Following Fragility Fractures in Women and Men with Rheumatoid Arthritis
Abstract Number: 823
Positive Effects of Tocilizumab On Bone Remodeling in Patients with Rheumatoid Arthritis
Abstract Number: 824
Progressive Improvements in Cortical Mass and Thickness throughout the Hip Were Observed with Denosumab Treatment in the Freedom Trial
Abstract Number: 1957
Prevalence and Associated Factors of Vitamin D Insufficiency and Deficiency in 4,793 Japanese Patients with Rheumatoid Arthritis
Abstract Number: 1958
Bone Mineral Density in Lupus Erythematosus Women One Year After Rituximab Therapy
Abstract Number: 1959
Low Fracture Incidence Is Maintained in Postmenopausal Women ≥75 Years with Osteoporosis with Long-Term Denosumab Treatment
Abstract Number: 1960
Initiation of Tumor Necrosis Factor Alpha (TNFα) Antagonists and Risk of Fractures in Patients with Selected Rheumatic and Autoimmune Diseases
Abstract Number: 1961
In Postmenopausal Women with Osteoporosis, Denosumab Significantly Improved Trabecular Bone Score (TBS), an Index of Trabecular Microarchitecture
Abstract Number: 1962
The Specific Role of Glutaredoxin2 Isoform b (Glrx2b) in RANKL-Induced Osteoclastogenesis Through Activation of the p38-MAPK Signaling Pathway
Abstract Number: 1963
Fracture Sites, Frequencies and Causes in 9,720 Japanese Patients with Rheumatoid Arthritis: A Prospective Observational Cohort Study
Abstract Number: 1964
Rolofylline, an Adenosine A1R Antagonist, Acts As an Inverse Agonist to Inhibit Osteoclast Differentiation
Abstract Number: 1965
Adenosine Regulates Bone Metabolism Via A1, A2A and A2B Receptors in Bone Marrow Cells From Normal and Patients with Multiple Myeloma
Abstract Number: 1966
Cost-Effectiveness of Bazedoxifene Compared with Raloxifene in the Treatment of Postmenopausal Osteoporotic Women
Abstract Number: 1967
Hypophosphatemic Osteomalacia Induced by Tenofovir in Patients with Human Immunodeficiency Virus Infection
Abstract Number: 1968
The Specific Role of Vesicle-Associated Membrane Protein-Associated Protein B/C(VapB) As a Regulator of Osteoclastogenesis Via Modulation of Phospholipase Cã(PLCã2-Ca2+-NFAT Signaling
Abstract Number: 1969
Correction of Vitamin D Insufficiency with the Fixed Daily Combination Strontium Ranelate 2 g/Vitamin D3 1000 IU Over 12 Months
Abstract Number: 1970
Utility of Spine Bone Mineral Density in Fracture Prediction within the Fracture Risk Assessment Tool (FRAX)
Abstract Number: 1971
Resolution of Effects On Bone Turnover Markers and Bone Mineral Density After Discontinuation of Long-Term Bisphosphonate Use
Abstract Number: 1972
Assessment of Fracture Risk in Postmenopausal Women with Rheumatoid Arthritis
Abstract Number: 1973
Effect of Adalimumab On the Serum Level of Undercarboxylated Osteocalcin (ucOC), Bone Biochemical Markers and Bone Mineral Density
Abstract Number: 1974
Incidence of Atypical Femur Fractures Associated with Bisphosphonate Use for Osteoporosis: A Systematic Review of the Literature
Abstract Number: 1975
Mortality After Fragility Hip Fracture in Middle Aged and Elderly Men and Women in Southern Norway
Abstract Number: 1976
Treatment Satisfaction in Postmenopausal Women Previously Treated with Bisphosphonates Who Transitioned to Denosumab Vs Ibandronate Therapy in an Open-Label Study
Abstract Number: 1977
Relationship Between Baseline Bone Turnover Marker Levels and Bone Mineral Density Changes in Men with Low Bone Mineral Density Receiving Denosumab or Placebo
Abstract Number: 1978
A Web-Based Intervention Aimed to Improve Bone Health Among Individuals On Chronic Glucocorticoids
Abstract Number: 1979
Care Gap in the Treatment of Patients with High Risk for Fractures in a Single Canadian Academic Center
Abstract Number: 1980
Intermittent Nitrate Use and Risk of Hip Fracture
Abstract Number: 1981
Low Body Mass Index, Medication Use and Social Factors Such As Smoking but Not Secondary Medical Disorders or Older Age May Be More Prevalent in Males with Low Bone Mineral Density
Abstract Number: 1982
Five Years of Treatment to Target in Early Active Rheumatoid Arthritis: Prevalence and Predictors of Vertebral Fractures
Abstract Number: 1983
Comparative Risk of Fracture in Men and Women with Human Immunodeficiency Virus
Abstract Number: 1985
The Effect of Calcium and Vitamin D On Bone Loss in an Epileptic Population
Abstract Number: 1986
Impaired Endothelial Function in Post-Menopausal Women with Osteoporosis
Abstract Number: 1987
A Comparison of Unilateral and Bilateral Hip BMD
Abstract Number: 1988
Zoledronate Efficacy and Safety in Active Paget’s Disease Long-Term Follow-up and Retreatment in Clinical Practice
Abstract Number: 1989
Risk Factors for Vertebral Fractures in Patients with Rheumatoid Arthritis – the Tomorrow Study –
Abstract Number: 1990
Risk of Falling Is Equivalent Between Patients with Rheumatoid Arthritis and Healthy Individuals – the Tomorrow Study-
Abstract Number: 1991
Effects of Odanacatib On the Distal Radius and Tibia in Postmenopausal Women: Improvements in Cortical Geometry and Estimated Bone Strength
Abstract Number: 1992
Anti-TNF Therapies Improve Bone Mineral Density At the Lumbar Spine of RA Patients by Decreasing Disease Activity and Suppressing Serum RANKL Levels
Abstract Number: 1993
Contribution of Lifestyle Factors to Healthy-Adherer Bias in Prevalent Users of Osteoporotic Drugs
Abstract Number: 1994
The Influence of Percentage Body Fat On Bone Mineral Density in Thin Patients
Abstract Number: 1995
What Are the Most Clinically Relevant and Feasible Pragmatic Osteoporosis Clinical Trial Designs?
Abstract Number: 1996
Are Changes in Bone Mineral Density Different Between Groups of Early Rheumatoid Arthritis Patients Treated According to a Tight Control Strategy with or without Prednisone, If Osteoporosis Prophylaxis Is Applied?
Abstract Number: 1997
Safety and Efficacy of Denosumab Vs Ibandronate in Postmenopausal Women Sub-Optimally Treated with Daily or Weekly Bisphosphonates: A Randomized, Open-Label Study
Abstract Number: 1998
Relationship Between Changes in Bone Mineral Density and Incidence of Fracture with 6 Years of Denosumab Treatment

« View all sessions from this meeting

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences